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Gastric cancer is the second most common cause of cancer-
related death in the world. A growing body of evidence indi-
cates that inflammation is closely associated with the initia-
tion, progression, and metastasis of many tumors, including 
those of gastric cancer. In addition, approximately 60% of 
the world’s population is colonized by Helicobacter pylori, 
which accounts for more than 50% of gastric cancers. While 
the role of inflammation in intestinal and colonic cancers is 
relatively well defined, its role in stomach neoplasia is still 
unclear because of the limited access of pathogens to the 
acidic environment and the technical difficulties isolating and 
characterizing immune cells in the stomach, especially in 
animal models. In this review, we will provide recent updates 
addressing how inflammation is involved in gastric malignan-
cies, and what immune characteristics regulate the patho-
genesis of stomach cancer. Also, we will discuss potential 
therapeutics that target the immune system for the efficient 
treatment of gastric cancer. (Gut Liver 2014;8:131-139)
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INTRODUCTION
Gastric cancer is the fourth and fifth most frequent cancer in 
men and women, respectively, and the second most common 
cause of cancer-related death in the world.1 While the overall 
incidence of gastric cancer is declining in the United States and 
Western Europe, it is still relevant in many Asian nations, parts 
of South America, and Eastern Europe. These regional varia-
tions are likely due to differences in a variety of environmental 
factors and differences in the prevalence of Helicobacter pylori 
infection.
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Anatomically, there are two types of gastric cancer. The first, 
gastric cardia (proximal) cancer, occurs in the top portion of 
the stomach near the gastroesophageal junction, and the sec-
ond, noncardia cancer, may be found in all other areas of the 
stomach. These two cancer types have different risk factors and 
incidence patterns. For example, noncardia cancer is commonly 
associated with H. pylori infection, while gastric cardia cancer 
seems not to be affected by H. pylori.2 On the other hand, cardia 
gastric cancer, rare at one time, is now increasing in Western 
nations for reasons that are still unclear, and it accounts for 
about 50% of all stomach cancer in men in the United States. 
Gastric adenocarcinomas are classified into well-differentiated 
and undifferentiated types, with the undifferentiated type being 
characterized by a diffuse presentation, i.e., gastritis throughout 
the stomach but no atrophy, and the differentiated type is clas-
sified by intestinal-type tumors and corpus-dominated gastritis 
with gastric atrophy and intestinal metaplasia.
Recent insight into the tumor microenvironment has begun 
to uncover the close association between cancer and inflam-
mation, which bears similarities to wounds that fail to heal. 
Approximately 20% of cancer deaths worldwide are associated 
with unresolved infection or chronic inflammation, and the 
prolonged inflammation can lead to gastric cancer, colorectal 
cancer, inflammatory bowel disease, hepatocellular carcinoma, 
and chronic pancreatitis.3 Unresolved inflammation generates 
a microenvironment that facilitates cellular transformation and 
the propagation of invasive disease, with chronic tissue dam-
age triggering a repair response including growth and survival 
factors, tissue-remodeling enzymes, and immune regulatory 
cytokines. These examples of aberrant immunity foster tumors, 
but appropriate immune responses can suppress or eliminate 
tumors via a cancer immunosurveillance system.4 However, the 
contribution of immune cell populations to either the pathogen-
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esis or protection in the stomach environment has been difficult 
to elucidate. Here, we highlight recent progress in defining the 
roles of the immune system in cancer pathology with a focus on 
gastric adenocarcinoma. 
HELICOBACTER INFECTION, GASTRITIS, AND STOMACH 
CANCER
H. pylori is now regarded as the main cause of chronic gas-
tritis and is classified as a gastric carcinogen. Correa5,6 proposed 
that chronic gastritis progresses to intestinal-type gastric cancer 
through histological changes that include atrophy, metapla-
sia, and dysplasia. Indeed, research has demonstrated that the 
inflammatory response to H. pylori evokes diverse neoplastic 
changes of the gastric epithelium.7,8 Thus, eradiation of H. py-
lori infection leads to positive outcomes in regards to atrophy, 
metaplasia, and genomic instability, accompanied by reduced 
inflammation in the stomach.9,10 However, antibiotic therapy not 
only eradicates H. pylori, but also other microorganisms that 
can drive the inflammatory microenvironment in the stomach, 
raising the possibility that other pathogens may also be associ-
ated with gastric neoplasia. This idea was supported by a study 
using transgenic FVB/N insulin-gastrin mice that develop spon-
taneous gastritis and epithelial neoplasia with 80% prevalence 
after H. pylori infection.11 When the mice were colonized under 
germ-free conditions, gastric carcinoma development induced 
by H. pylori infection was substantially delayed compared to 
the mice maintained with conventional flora.12
While more than 50% of the world’s population is infected 
with H. pylori, only 10% to 15% of individuals infected with 
H. pylori develop peptic ulcers, and the risk of gastric cancer is 
estimated to be approximately 1% to 3%.1,13 This observation 
indicates that the disease progression of H. pylori-infected in-
dividuals depends on the presence of bacterial virulence factors 
and the types of host responses. The bacterial factors that allow 
H. pylori to colonize in the stomach and induce atrophic gastri-
tis have been studied through the use of isogenic mutants and 
genomic analyses of the bacteria, and the crucial factors that are 
required for persistence of the infected bacteria include urease 
and flagella. H. pylori secretes large amounts of urease to hy-
drolyze urea to ammonia and carbon dioxide, which neutralizes 
gastric acid, providing a local environment supporting bacterial 
survival.14 In addition, colonization of H. pylori on the mucus 
layer depends on the presence of flagella and the production of 
enzymes that break down the surfactant layer over the gastric 
epithelium.14 
Two genetic loci, cag and vacA, that link virulence factors 
to gastritis have been intensively studied. Infection with H. 
pylori strains that contain the cag locus, a 40 kb region known 
as the cag pathogenicity island (cag PAI), exhibit a higher risk 
for gastric cancer (especially intestinal-type adenocarcinoma) 
than infection with strains that do not contain the cag PAI.15 
On the other hand, the cag PAI is unlikely to be responsible for 
the pathogenesis of diffused-type gastric carcinoma, although it 
is associated with H. pylori infection.15 The functional protein, 
CagA, is encoded by the cag PAI, and is an immunodominant 
protein produced by H. pylori. Infection with H. pylori trans-
locates CagA protein into the host epithelial cells by a type 
IV secretion system, which is also encoded by cag PAIs. Once 
injected into the gastric epithelium, CagA is phosphorylated by 
Src family kinases and then activates SHP2 and Erk, which re-
sult in actin-cytoskeletal rearrangements and cell scattering.14,16 
Moreover, gene products of cag PAIs can directly elicit inflam-
mation via production of the interleukin (IL)-8 chemokine and 
through nucleotide-binding oligomerization domain-1 (NOD1). 
IL-8 induction by H. pylori infection depends on the presence 
of specific cagA genes and is mediated by MAPK and nuclear 
factor κB (NF-κB) signaling pathways in a SHP2-independent 
manner.17,18 NOD1, a pattern recognition receptor for the innate 
immune response, detects H. pylori infection by sensing a pep-
tidoglycan produced by cag PAIs, and instructs the production 
of proinflammatory cytokines such as IL-1β, IL-8, and tumor 
necrosis factor-α (TNF-α).19 
One crucial virulence factor secreted for the pathogenesis of 
stomach dysplasia is the vacuolating cytotoxin (Vac) encoded 
by the vacA gene.20,21 In a Mongolian gerbil model, infection 
with an adapted H. pylori strain lacking VacA reduced the in-
cidence of gastric carcinoma.22,23 Interestingly, the loss of CagA 
was protective in cancer development by attenuating inflam-
mation in this model, while ablation of VacA did not affect 
inflammation.22 However, the secreted pore-forming VacA toxin 
can indirectly augment inflammatory responses. For example, 
human gastric epithelial cells are highly susceptible to VacA-
induced cell death, and this programmed necrotic pathway 
contributes to the pathogenesis of peptic ulceration and gastric 
cancer by enhancing mucosal inflammation.24,25 
In addition to the direct effect of the virulence factors on the 
gastric epithelium, inflammation induced by H. pylori infection 
results in altered patterns of host DNA modification, which is 
closely associated with cancer risk. Temporal analysis showed 
that levels of DNA methylation in gastric epithelial cells were 
increased by H. pylori infection, which was paralleled by the 
induction of inflammation-related genes encoding IL-1β, NOS2, 
and TNF-α.26 Suppressing inflammation with cyclosporine A 
treatment did not affect bacterial colonization, but treatment 
did attenuate the induction of DNA methylation, suggesting 
that the infection-induced inflammatory response, rather than H. 
pylori itself, is responsible for the genetic alteration of the gas-
tric epithelium. Despite the notion that H. pylori evokes a strong 
inflammatory response, the immune system is likely to be in-
sufficient to clear the infection due to the pathogen’s immune 
evasion strategies. The mechanisms for immune evasion include 
the induction of a strong, polarized immune response, modula-
tion of phagocytosis and neutrophil function, and inhibition of 
Lee K, et al: Immune Cells Modulate Gastric Pathogenesis  133
lymphocyte proliferation.14 Thus, prolonged inflammation and 
direct action of bacterial factors may simultaneously lead to im-
paired gland function and eventually to carcinogenesis. 
HOST IMMUNE SYSTEM AND GASTRIC CANCER
A large body of evidence suggests pivotal roles for host fac-
tors in determining the progression of the gastric pathogenesis. 
The stroma of gastric tumors is frequently filled with a wide 
range of white blood cells, but whether these inflammatory 
cells are responsible for the initiation and/or the progression of 
gastric pathogenesis remains undetermined. Genetic studies of 
patients with gastric atrophy, hypochlorhydria, and carcinoma 
revealed an increased incidence of genetic alterations strongly 
associated with host immune responses. Bone marrow-derived 
populations that constitute the inflammatory microenvironment 
of the stomach include granulocytes, macrophages, myeloid-
derived suppressor cells (MDSCs), and dendritic cells, as well as 
adaptive immune cells such as T and B cells (Figs 1 and 2).
1. Innate immune response
1) Neutrophils
Neutrophils are the most abundant circulating granulocyte 
population and are recruited to the inflamed tissue immediately 
or early after infection or tissue damage. Pathogen-induced 
IL-8 expression from the stroma mobilizes neutrophils into the 
infected lesion and activates the cells to produce antimicrobial 
peptides and reactive oxygen species.27 Moreover, the activated 
neutrophil production of IL-8 is important for the initiation of 
adaptive immunity by recruiting T cells. Forced expression of 
human IL-8 in mice is sufficient to accelerate colonic and gas-
tric carcinogenesis induced chemically and by H. felis infection, 
respectively.28 Of note is that CD11b+ Gr1+ myeloid cell levels 
increase systemically and locally in IL-8 transgenic mice, and 
these cells contribute to tumor microenvironment remodeling. 
These studies suggest that targeting IL-8 may be a useful thera-
peutic for inflammation-associated carcinogenesis, although 
further characterization of the myeloid populations is needed.   
2) Tumor-associated macrophages
Tumor-associated macrophages (TAMs) are a heterogeneous 
population, and accumulation of these cells in the neoplastic 
area indicates a poor prognosis.29 In a gastric cancer model us-
ing K19-Wnt1 transgenic mice, macrophages accumulate in 
the dysplastic mucosa, accompanied by nuclear induction of 
β-catenin in the epithelium.30 Intriguingly, depletion of macro-
phages from APC (Δ716) mice mitigates intestinal tumor forma-
tion, suggesting that inflammation induced by macrophages 
contributes to the pathogenesis of the gastric mucosa via Wnt/
β-catenin signaling. An example of how macrophages directly 
affect the pathogenesis of the gastric epithelium is by the pro-
duction of nitric oxide (NO). Specifically, macrophages activated 
by H. pylori infection produce NO that causes methylation of 
genes associated with tumor suppression, such as Runx3, in the 
epithelial cells. Thus, treatment with an NO-specific inhibitor 
Fig. 1. Innate immune cells associated with gastric pathogenesis. 
NO, nitric oxide; MMP, matrix metalloproteinase; IL, interleukin; TIL, 
tissue infiltrating lymphocyte; MDSC, myeloid-derived suppressor 
cell; CAF, carcinoma-associated fibroblast.
Fig. 2. Helper T cell subsets and gas-
tric neoplasia. 
IL, interleukin; TGF, transforming 
growth factor; IFN, interferon.
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can reverse H. pylori-induced methylation of the gut epithelium, 
providing a mechanism by which H. pylori causes epigenetic 
changes associated with gastric malignancy through inflamma-
tion.
Depending on the cytokine expression profiles, there are two 
distinct types of macrophages.31 M1 macrophages are activated 
by interferon-γ (IFN-γ) and microbial components such as lipo-
polysaccharides (LPS), they express high level of class II major 
histocompatibility complex (MHC) molecules, and they produce 
proinflammatory cytokines including IFN-γ and TNF-α. Alter-
natively, M2 macrophages are activated by IL-4, have reduced 
antigen presentation characteristics and tumoricidal activity, 
and produce the immunosuppressive cytokine, IL-10. Accord-
ingly, in the area of solid tumors, accumulation of M2 macro-
phages, which are involved in wound healing and tissue remod-
eling in normal physiology, is associated with a poor prognosis, 
whereas tumor infiltration of M1 macrophages could elicit a 
protective immune responses against the tumor.31,32 However, 
it is hard to distinguish between M1 and M2 TAMs in gastric 
tumors because they partially share cytokine profiles that are 
unlikely to be observed in vitro. 
3) IL-1β and MDSCs 
Polymorphisms of a gene encoding IL-1β are well known 
to be high risk factors for intestinal disorders such as Crohn 
disease.33,34 IL-1β inhibits acid secretion in the stomach, and 
genetic variations in the IL-1β locus that includes IL-1β and 
IL-1RN, a soluble IL-1 receptor antagonist, are also associated 
with gastric atrophy and adenocarcinoma.35 The functional role 
of IL-1β in gastric inflammation and cancer was reported us-
ing a transgenic mouse expressing human IL-1β specifically 
in the stomach.36 These transgenic mice developed spontane-
ous inflammation and gastric tumors that correlated with early 
recruitment and activation of MDSCs, a population having the 
capacity to inhibit inflammatory T cell responses.37 Interestingly, 
administration of neutralizing antibody against the IL-1 recep-
tor attenuated the gastric dysplasia, which was accompanied 
by a marked decrease in MDSC infiltration to the stomach. This 
study proposed an immune evasion mechanism for gastric tu-
mors with sustained chronic inflammation, and suggested that 
the proinflammatory cytokine, IL-1β, can elicit immunosup-
pressive function by recruiting MDSCs. In addition, MDSCs can 
directly induce tumor progression and metastasis by producing 
matrix metalloproteinases that facilitate tumor invasion.38 In ad-
dition, the conditional deletion of p120 catenin in mice leads to 
esophageal squamous cancer accompanied by the recruitment 
of MDSCs to the dysplastic epithelium.39 These results support 
the finding that mobilization of MDSCs to the gastric epithe-
lium provides a microenvironment to promote inflammation-
associated dysplasia.
4) Toll-like receptor
Toll-like receptors (TLRs) sense pathogen-associated molecular 
patterns to mediate an immediate-early host response to the in-
fectious microorganisms. Specifically, TLR4 recognizes the LPS 
of gram-negative bacteria and induces expression of proinflam-
matory cytokines such as IL-1β, TNF-α, and IL-8.40 LPS from H. 
pylori upregulates TLR4 expression in gastric cancer cells and 
then induces proliferation of the cells.41 The TLR4 A896G poly-
morphism is linked to an impaired response to LPS, and genetic 
analysis of patients with hypochlorhydria and gastric atrophy 
revealed that this genetic variation is positively correlated with 
the severity of gastric atrophy and inflammation.40,42 Although 
it was not associated with gastric acid output in the absence of H. 
pylori infection, this genetic alteration is a strong risk factor for 
noncardia gastric carcinoma induced by the host’s innate im-
mune response in H. pylori infection. Distinct from TLR4, TLR2 
is involved in a wide array of microbial molecules that include 
peptidoglycans, lipoteichoic acid, lipoproteins, and zymosan.40 
Through TLR2 signaling, Listeria monocytogenes stimulates 
proliferation of tumor cells by increasing production of NO and 
IL-6, without affecting infiltration of MDSCs or regulatory T 
cells.43 The effects of H. pylori infection in gastric tumor cells is 
shared with those of Listeria, such that silencing TLR2 expres-
sion abrogates the bacteria-induced tumor cell proliferation. 
5) INF-γ receptor 1
Another polymorphism of inflammation-related genes associ-
ated with the risk of gastric cancer was found in a gene encod-
ing the INF-γ receptor 1 (Ifngr1). Individuals having polymor-
phisms in Ifgnr1 are more susceptible to H. pylori infection, and 
a case-control study revealed a strong correlation between the 
onset of gastric cancer and a specific genotype (C-56T) in the If-
ngr1 promoter region.44 This genetic variation is a relevant host 
factor that predicts early development of gastric cancer. Using 
a transgenic mouse model, the potential role of this cytokine in 
gastric tumorigenesis was evaluated. Under the control of the 
stomach-specific H+/K+ ATPase promoter, transgenic expression 
of IFN-γ resulted in proliferation of undifferentiated and meta-
plastic epithelial cells along with elevated expression of proin-
flammatory cytokines that include IL-6, IL-1β, and TNF-α.45 The 
mice exhibited dysplasia at as early as 3 months of age, and 
some mice developed antral polyps, suggesting IFN-γ as a cru-
cial inflammatory factor that drives preneoplastic progression in 
the stomach. Nonetheless, IFN-γ involved in the type 1 helper T-
cell response may have a protective role in gastric pathogenesis, 
will be discussed later.
6) Carcinoma-associated fibroblasts  
Carcinoma-associated fibroblasts (CAFs) that express α-smooth 
muscle actin function like a tissue-resident immune cell and 
contribute to cancer progression. Quante and colleagues46 found 
that some (about 20%) of the CAFs originate in bone marrow 
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and increased markedly during cancer progression. In response 
to transforming growth factor β (TGF-β) and stromal cell-
derived factor-1α, CAFs are generated and recruited to the dys-
plastic tumor, suggesting a role for this bone marrow-derived 
cell in sustaining tumor progression. This suggested role was 
supported by a report showing that in response to H. pylori in-
fection, bone marrow populations mobilized to the stomach and 
differentiated into a fibroblast lineage that participated in the 
gastric neoplasia.47 Chimeric mice transplanted with bone pro-
genitor cells expressing GFP develop gastric dysplasia when in-
fected with H. pylori, in addition to chronic inflammation. More 
than 20% of the dysplastic lesions were composed of glands 
that contained epithelial bone marrow-derived cells.
7) IL-6 family  
Intracellular signaling mechanisms that specify tissue-specific 
responses to the IL-6 family of cytokines are emerging to be 
crucial for inflammation-induced neoplasia. Knocking-in a 
GP130 mutation, a shared subunit of receptors for IL-6 family 
cytokines, resulted in gastric adenomas by 3 months of age, and 
the adenoma displayed many of the characteristics of human 
intestinal-type gastric cancer.48 Loss of a STAT3 or IL-6 allele 
in the mutant GP130 mice resulted in a reduced frequency and 
rate of tumor development due to the inhibition of proliferation-
induced glandular hyperplasia.49,50 The mice exhibited a reduc-
tion in the recruitment of inflammatory cells such as macro-
phages and neutrophils, cytokine expression, angiogenesis, and 
metalloproteinase expression, which was similarly observed in 
the mice treated with an antimicrobial agent. These results sup-
port the notion that IL-6-induced STAT3 activation plays a cru-
cial role in inflammation-induced gastric cancer development. 
Moreover, another group reported an unexpected correlation 
between TLR2 and STAT3, in which STAT3 upregulated TLR2 
expression in the gastric epithelium.51 Genetic and therapeutic 
targeting of TLR2 in the gastric cancer mouse model inhibited 
gastric tumorigenesis, but not inflammation. Furthermore, in-
creased activation of STAT3 and TLR2 were inversely correlated 
with gastric cancer patient survival.51 Collectively, in addition 
to the impact on immune function, STAT3-dependent TLR2 
activation has an oncogenic function in a gastric epithelial cell-
intrinsic manner. 
2. Adaptive immune response
1) Effector versus regulatory T cells  
Appropriate T cell responses are important for the clearance 
of chronic bacterial infection, while it is still unclear how H. py-
lori infection evokes adaptive immunity and how this pathogen 
evades immune surveillance to survive in specialized organs. 
For proper infection clearance, naïve T cells differentiate into 
effector T cell subsets that include type 1 helper T (Th1) cells for 
intracellular viruses and tumors, type 2 (Th2) cells for helmin-
thic worms, and type 17 (Th17) cells for extracellular bacteria, 
especially in the intestine.52 On the other hand, regulatory T 
cells (Treg cells) that express the FoxP3 transcription factor and 
anti-inflammatory cytokine, IL-10, are important for peripheral 
tolerance, and balance between effector T cells and Treg cells is 
crucial for the resolution of chronic inflammation. Recent stud-
ies focus on tumor-infiltrating lymphocyte (TIL) populations 
that are associated with disease outcomes in various human 
cancers.53,54 However, the prognostic role of TILs in patients with 
gastric cancer still remains to be determined. 
Flow cytometry analysis of human subjects with or without 
H. pylori infection indicated that the bacteria-induced immune 
response includes both Th1 and Th2 subsets with high levels 
of anti-inflammatory Treg cells.55 Intriguingly, individuals 
with peptic ulcers exhibited reduced IL-10+ Treg responses but 
increased Th1 and Th2 responses compared to those without 
ulcers. These results indicate a modulatory mechanism of Treg 
cells in the H. pylori-induced inflammatory environment, but 
otherwise, gastritis occurs when this regulatory response is 
inadequate. Other example that H. pylori infection can induce 
systemic Treg cells has been shown in a murine asthma model. H. 
pylori infection efficiently protected mice from airway hyper-
sensitiveness, tissue inflammation, and goblet cell metaplasia, 
which are hallmarks of asthma.56 The accumulation of highly 
suppressive Treg cells in the lungs was associated with asthma 
protection, and this Treg accumulation was accompanied by a 
reduction in allergen-induced lung infiltration of eosinophils, 
Th2 cells, and Th17 cells, a response that was abolished with 
antibiotic eradication of H. pylori or systemic Treg depletion. 
These results provide experimental evidence for a competitive 
effect of H. pylori colonization on the development of allergen-
induced asthma.
2) TGF-β signaling
TGF-β-deficient mice spontaneously develop gastritis, which 
is associated with an exaggerated Th1 response, character-
ized by IFN-γ production and reduced induction of Treg cells.57 
Analysis of patient samples infected with H. pylori infection re-
vealed defective TGF-β1-induced Smad3 phosphorylation in the 
H. pylori-infected whole biopsy specimens and isolated mucosal 
cells.58 Although activated TGF-β1 was abundant in the mucus, 
H. pylori infection results in increased expression of Smad7, 
which inhibits Smad3 functions. Antisense treatment for Smad7 
is sufficient for restoring TGF-β1-induced Smad3 phosphory-
lation in the biopsy specimens, which is followed by reduced 
expression of the Th1 subset markers IFN-γ and T-bet.58 These 
data suggest that the downregulation of TGF-β1 signaling by 
H. pylori infection promotes the ongoing tissue-damaging Th1 
response. 
3) IFN-γ
Although chronic infection with H. pylori upregulates the 
proinflammatory Th1 response, the effect of the Th1 cytokine 
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IFN-γ on inflammation-associated gastric carcinogenesis is 
debatable. In contrast to the expected proinflammatory ef-
fect, targeted expression of IFN-γ in a transgenic mouse under 
the control of the H+/K+-ATPase failed to induce gastritis, and 
instead, inhibited gastric carcinogenesis driven by IL-1β and/
or H. pylori infection.59 Expression of IFN-γ inhibited Th1 and 
Th17 immune responses through Fas induction and apoptosis 
of CD4 T cells, and evoked autophagy in gastric epithelial cells 
by increasing Beclin-1. These results were far different than the 
results observed in the above-described IFN-γ transgenic mice 
that spontaneously develop spasmolytic polypeptide expressing 
metaplasia and dysplasia.45 This discrepancy might be explained 
by differences in the amount of IFN-γ produced and the cyto-
kine milieu in the mutant mouse lines. Thus, overexpression of 
IFN-γ in concert with proinflammatory cytokines such as IL-6 
can promote gastritis and dysplasia, while moderate expression 
of IFN-γ can elicit a coordinated function that eliminates the 
infection and modulates chronic inflammation by inducing an 
autophagic program.
4) Th17 cells
While Th17 cells are essential for the homeostasis of and 
protection against intestinal bacterium, implications of this 
helper T-cell subset in the stomach are unclear. Several lines of 
experimental evidence recently suggested a potential role for 
the Th17 cytokine, IL-17, in gastric carcinogenesis. Stimula-
tion of human gastric cancer cell lines, including AGS, with IL-
17A induces NF-κB activation and IL-8 production, which is 
abrogated by inhibition of IL-17 receptors using siRNAs.60 In 
addition, a genetic polymorphism of the IL-17 gene in gastric 
carcinogenesis has been reported.61 The study showed that the 
197A polymorphism of the IL-17A gene was significantly corre-
lated with both the inflammation score and the risk of develop-
ing gastric mucosal atrophy, especially in intestinal-type cancer 
compared to diffuse-type cancer. Furthermore, the Iida group62 
analyzed human gastric tumors by immunohistochemistry, and 
they observed infiltration of CD4+ IL-17+ cells and upregulation 
of mRNA of the Th17-associated cytokines IL-17, IL-21, and 
IL-23 in the tumor tissues compared to normal tissues. It was 
intriguing that the number of vascular endothelial cells and 
neutrophils were markedly increased in tumors expressing high 
level of IL-17 compared those expressing a low IL-17 levels. 
Overall, these studies suggest a pivotal role for the Th17 subset 
in the persistence of inflammation and gastric neoplasia. 
In the presence of TGF-β, IL-6, and IL-23-naive CD4 T cells 
differentiate into the Th17 subset, and these factors might be en-
riched in the tumor microenvironment.63 Gastric myofibrobalsts 
(GMFs) express high levels of class II MHC and are thought to 
act as antigen-presenting cells in the gastric mucosa. When CD4 
T cells differentiate under the Th17-polarizing conditions, GMFs 
isolated from patients with gastric cancer or infected with H. 
pylori substantially enhanced Th17 induction compared to the 
cells from normal tissues.64 This study provides a mechanism by 
which Th17 cells are enriched in the inflammatory milieu of the 
gastric stroma and provide a link between inflammation and 
carcinogenesis.
In contrast, the Kennedy group65 claimed that Th17 responses 
are not directly associated with the pathogenesis of gastric tu-
mors. Knock-in mice with the pp130(F/F) allele spontaneously 
develop gastric inflammation-associated tumors akin to human 
intestinal-type gastric cancer. This mutation leads to hyper-
activation of STAT3 via the stimulation of IL-6 family cyto-
kines.50 In these mice, generation of Th17 cells and the gastric 
expression of Th17-related factors such as IL-17a, Rorγt, and IL-
23 were augmented. However, genetic ablation of IL-17A did 
not suppress the initiation and growth of gastric tumors in the 
gp130(F/F) background. Moreover, IL-17A and Rorγt expression 
was strongly increased in patients with gastritis but not gastric 
cancer, suggesting that increased expression of Th17-related 
factors does not correlate with the progression of gastric tumor-
igenesis. In other reports, however, flow cytometric analysis of 
peripheral blood from patients with gastric cancer showed that 
circulating Th17 cells are positively correlated with the stage of 
gastric cancer,66 implying that Th17 cells contribute to the gas-
tric tumor.
5) B cells and Th2 cells
Although H. pylori-induced chronic atrophic gastritis is 
characterized by marked infiltration of Th1 and Th17 cells, the 
majority of the inflamed gastric mucosa also contains focal 
lymphoid aggregates with germinal centers.67 Autoantibodies 
against tumor-associated antigens are very attractive biomark-
ers for the development of serological tests for early cancer 
detection. Recently, phage display-based serological analyses 
have identified a representative set of antigens eliciting hu-
moral responses in patients with gastric cancer,68 although it is 
unknown whether these B-cell responses are sufficient to cause 
gastric pathology. Typical H. pylori-induced chronic gastritis in 
children, which is called follicular gastritis, is characterized by 
B-cell follicles in the gastric mucosa.69 Thus, B-cell activation 
and cognate Th2 cell’s help can be composed in the pathogen-
induced inflammatory responses. Kido and his colleagues69 
found that H. pylori directly induced production of thymic 
stromal lymphopoietin (TSLP) from the epithelial cells in human 
follicular gastritis and that TSLP-mediated dendritic cell activa-
tion is involved in the Th2 response to activate B cells in the 
pathogen-driven gastritis. 
DIAGNOSIS AND THERAPEUTIC TARGETING IMMUNITY
A high density of cytotoxic CD8 T cells and memory T cells 
are usually associated with better outcomes in gastric cancer, 
indicating the crucial role of adaptive immunity in the tumor 
immunosurveillance system.70 On the other hand, the prevalence 
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of suppressor cells may prove to be a decisive factor for poor 
outcomes because MDSC and Treg cells restrain the antitumor 
activity of cytotoxic T cells. Indeed, analysis of patients with 
hepatocarcinoma revealed that a high ratio of cytotoxic T cells 
to Treg cells was linked to increased survival, whereas a low 
ratio was associated with tumor vascular invasion and inferior 
survival.71 In this context, the type, density, and intratumoral 
location of the leukocyte infiltrate has been shown to be a more 
informative biomarker than the TNM or Duke’s classification.72 
Programmed death-1 (PD1) is a negative regulator of effector 
T cell function.73 Signaling through PD1 is triggered by engage-
ment of the ligands PD-L1 or PD-L2, and intriguingly, some tu-
mors upregulate expression of PD-L1, resulting in a dampened 
cytotoxic T-cell response. Actually, patients with pancreatic ad-
enocarcinoma exhibit high levels of intratumoral PD-L1, which 
is accompanied by decreased T-cell infiltration and poor surviv-
al, suggesting an immune-evasion mechanism.74 One promising 
therapy is antibody blockade of the interaction between PD1 
and PD-L1, which is undergoing clinical trials. Another promis-
ing target for cancer therapy involves cytotoxic T cell antigen-4 
(CTLA-4). Treatment with monoclonal antibodies against CTLA-
4 augments the antitumor activity of effector T cells and results 
in improved patient survival in advanced melanoma.75 Evalua-
tion of this antibody therapy is ongoing in the adjuvant setting 
for gastric cancer.
CONCLUDING REMARKS
While bacterial virulence factors are crucial determinants of 
disease outcomes, the host defense system also plays a role by 
eliciting an immune response to clear H. pylori infection, which 
results in a robust gastritis followed by a series of pathologi-
cal changes that progress to cancer. Antibiotic intervention 
to eradicate H. pylori early in this pathological process might 
be protective against more severe disease. However, it is still 
unclear whether patients with advanced, premalignant lesions 
can benefit from antibiotic treatment. Alternatively, mediators 
of chronic inflammation could serve as potential therapeutic 
targets to suppress the gastric pathogenesis. For example, in the 
setting of achlorhydria, sustained tissue damage in the stomach 
due to chronic inflammation leads to cancer in part by affect-
ing recruitment of immune cell populations, thereby altering 
the tumor microenvironment. Thus, we should translate our 
knowledge of the tumor microenvironment into clinical trials, 
such as those that combine drugs targeting inflammation with 
conventional chemotherapies.
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